Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/15/2020 (updated 3/28/2024)
The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.
Posted 5/27/2020 (updated 3/28/2024)
Please see attached technical modules to help guide you as you work to address the opioid epidemic in your communities. They are a resource for you to identify best practices and implementation models for prevention, treatment, and recovery.
Posted 11/9/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) published Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants in 2018. The National Center on Substance Abuse and Child Welfare (NCSACW) developed companion materials that offer information and strategies to support pregnant and parenting people with substance use disorders (SUDs) in the child welfare system.
Posted 4/11/2023 (updated 3/27/2024)
This webinar will help set a foundation for what trauma-informed care (TIC) means and why it is important.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.